Literature DB >> 15099018

Meningioma pathology, genetics, and biology.

Katrin Lamszus1.   

Abstract

Over the past 5 to 10 years, important advances were made in the understanding of meningioma biology. Progress in molecular genetics probably represents the most important accomplishment in the comprehensive knowledge of meningioma pathogenesis. Several genes could be identified as targets for mutation or inactivation. Additional chromosomal regions were found to be commonly deleted or amplified, suggesting the presence of further tumor suppressor genes or proto-oncogenes, respectively, in these regions. Histopathologically, the most important innovation is represented by the revised WHO classification in the year 2000. Meningioma grading criteria in the new classification scheme are more precise and objective, and should thus improve consistency in predicting tumor recurrence and aggressive behavior. This review focuses mainly on the advances in molecular biology that were achieved in recent years. It summarizes the most important aspects of meningioma classification as the basis to place biological observations into a correlative context, and, further, includes mechanisms of angiogenesis and edema formation as well as the role of hormone receptors in meningiomas.

Entities:  

Mesh:

Year:  2004        PMID: 15099018     DOI: 10.1093/jnen/63.4.275

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  39 in total

Review 1.  Update on meningiomas.

Authors:  Santosh Saraf; Bridget J McCarthy; J Lee Villano
Journal:  Oncologist       Date:  2011-10-25

2.  Comparative protein profiling reveals minichromosome maintenance (MCM) proteins as novel potential tumor markers for meningiomas.

Authors:  Okay Saydam; Ozlem Senol; Tieneke B M Schaaij-Visser; Thang V Pham; Sander R Piersma; Anat O Stemmer-Rachamimov; Thomas Wurdinger; Saskia M Peerdeman; Connie R Jimenez
Journal:  J Proteome Res       Date:  2010-01       Impact factor: 4.466

3.  Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.

Authors:  Andrew D Norden; Jeffrey J Raizer; Lauren E Abrey; Kathleen R Lamborn; Andrew B Lassman; Susan M Chang; W K Alfred Yung; Mark R Gilbert; Howard A Fine; Minesh Mehta; Lisa M Deangelis; Timothy F Cloughesy; H Ian Robins; Kenneth Aldape; Janet Dancey; Michael D Prados; Frank Lieberman; Patrick Y Wen
Journal:  J Neurooncol       Date:  2009-06-28       Impact factor: 4.130

4.  WHO grade II and III meningiomas: a study of prognostic factors.

Authors:  Anne Durand; François Labrousse; Anne Jouvet; Luc Bauchet; Michel Kalamaridès; Philippe Menei; Robert Deruty; Jean Jacques Moreau; Michelle Fèvre-Montange; Jacques Guyotat
Journal:  J Neurooncol       Date:  2009-06-27       Impact factor: 4.130

5.  Angiogenesis and expression of estrogen and progesterone receptors as predictive factors for recurrence of meningioma.

Authors:  Patricia Guevara; Elizabeth Escobar-Arriaga; David Saavedra-Perez; Abelardo Martinez-Rumayor; Diana Flores-Estrada; Daniel Rembao; Alejandra Calderon; Julio Sotelo; Oscar Arrieta
Journal:  J Neurooncol       Date:  2009-12-15       Impact factor: 4.130

6.  Expression of CD163 prevents apoptosis through the production of granulocyte colony-stimulating factor in meningioma.

Authors:  Hiromi Kanno; Hiroshi Nishihara; Lei Wang; Sayaka Yuzawa; Hiroyuki Kobayashi; Masumi Tsuda; Taichi Kimura; Mishie Tanino; Shunsuke Terasaka; Shinya Tanaka
Journal:  Neuro Oncol       Date:  2013-03-28       Impact factor: 12.300

7.  Decreased expression of LASS2 is associated with worse prognosis in meningiomas.

Authors:  Rong-Hu Ke; Yin Wang; Yin Mao; Jun Zhang; Ji Xiong
Journal:  J Neurooncol       Date:  2014-04-17       Impact factor: 4.130

Review 8.  Medical management of meningiomas.

Authors:  Wendy J Sherman; Jeff J Raizer
Journal:  CNS Oncol       Date:  2013-03

9.  Microarray analysis reveals down-regulation of the tumour suppressor gene WWOX and up-regulation of the oncogene TYMS in intracranial sporadic meningiomas.

Authors:  Mads Aarhus; Ove Bruland; Geir Bredholt; Helle Lybaek; Eystein S Husebye; Bård K Krossnes; Christian Vedeler; Knut Wester; Morten Lund-Johansen; Per M Knappskog
Journal:  J Neurooncol       Date:  2008-03-26       Impact factor: 4.130

10.  Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth.

Authors:  Marianne F James; Johanna M Lelke; Mia Maccollin; Scott R Plotkin; Anat O Stemmer-Rachamimov; Vijaya Ramesh; James F Gusella
Journal:  Neurobiol Dis       Date:  2007-09-19       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.